Sign in

IPHA on Nasdaq

Innate Pharma SA

Innate Pharma SA is a biological products company, listed on Nasdaq (IPHA).1

Price unavailable

Last updated Oct 21, 2026.

Overview

9.0MRevenue, fiscal 20252
-49.2MNet income, fiscal 20252

Compare with Argenx SE or Valneva SE, or pick any stock.

  • TickerIPHA on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersI01
  • Incorporated inFrance3
  • Business address117 Avenue De Luminy, Bp 30191, Marseille, 130093
  • Filer categoryAccelerated filer3

See how the biggest companies compare on our leaderboards

Chief Executive Officer. The Board of Directors then decided, on the same day, following the Annual General Meeting, to separate the functions of Chairman of the Board and Chief Executive Officer (see “Item 6. Directors, Senior Management and Employees—A. Directors and Senior Management”). Innate's headquarters are located at 117, Avenue de Luminy, 13009 Marseille, France. In 2008, The Company incorporated its wholly owned U.S. subsidiary, Innate Pharma Inc. In 2019, Innate Pharma's incorporated its wholly owned French subsidiary, Innate Pharma France S.A.S. (registered under number SIREN 844 853 119). Innate Pharma France S.A.S. was dissolved without liquidation on November 30, 2020, under article 1844-5, Section 3 of the French Civil Code.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2025

-599.8%Operating margin2
-546.1%Net margin2
-55.2%Revenue growth, 20252
-52.9M EURFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development99¢43.6M EUR
  • Interest1¢440.0K EUR

Out of 9.0M EUR in revenue.2 The company lost money this year.

Financial statements

Revenue5678929.0M EUR in 2025−90% since 2018
025.0M EUR50.0M EUR75.0M EUR100.0M EUR2018: 94.0M EUR94.0M EUR20182019: 85.4M EUR85.4M EUR2019−9%2020: 69.8M EUR69.8M EUR2020−18%2021: 24.7M EUR24.7M EUR2021−65%2022: 57.7M EUR57.7M EUR2022+133%2023: 61.6M EUR61.6M EUR2023+7%2024: 20.1M EUR20.1M EUR2024−67%2025: 9.0M EUR9.0M EUR2025−55%
Operating income567892-54.0M EUR in 2025
-60.0M EUR-40.0M EUR-20.0M EUR020.0M EUR2018: 5.1M EUR5.1M EUR20182019: 1.6M EUR1.6M EUR2019−69%2020: 1.1M EUR1.1M EUR2020−31%2021: -47.8M EUR-47.8M EUR20212022: -57.4M EUR-57.4M EUR2022+20%2023: -12.7M EUR-12.7M EUR2023−78%2024: -51.6M EUR-51.6M EUR2024+307%2025: -54.0M EUR-54.0M EUR2025+5%
Net income567892-49.2M EUR in 2025
-80.0M EUR-60.0M EUR-40.0M EUR-20.0M EUR020.0M EUR2018: 3.0M EUR3.0M EUR20182019: -20.8M EUR-20.8M EUR20192020: -64.0M EUR-64.0M EUR2020+208%2021: -52.8M EUR-52.8M EUR2021−17%2022: -58.1M EUR-58.1M EUR2022+10%2023: -7.6M EUR-7.6M EUR2023−87%2024: -49.5M EUR-49.5M EUR2024+554%2025: -49.2M EUR-49.2M EUR2025−1%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Revenue from collaboration and licensing agreements2.8M EUR12.6M EUR51.9M EUR
Government financing for research expenditures6.2M EUR7.5M EUR9.7M EUR
Other income13.0K EUR11.0K EUR11.0K EUR
Total revenue and other income9.0M EUR20.1M EUR61.6M EUR
Research and development expenses-43.6M EUR-52.0M EUR-56.0M EUR
General and administrative expenses-19.4M EUR-19.7M EUR-18.3M EUR
Impairment of intangible assets0 EUR0 EUR0 EUR
Total operating expenses-63.0M EUR-71.7M EUR-74.3M EUR
Operating income (loss)-54.0M EUR-51.6M EUR-12.7M EUR
Financial income8.0M EUR6.1M EUR6.9M EUR
Financial expenses-3.1M EUR-4.0M EUR-1.8M EUR
Net financial income (loss)4.8M EUR2.1M EUR5.1M EUR
Net income (loss) before tax-49.2M EUR-49.5M EUR-7.6M EUR
Income tax expense0 EUR0 EUR0 EUR
Net income (loss) from continuing operations-49.2M EUR-49.5M EUR-7.6M EUR
Net income (loss)-49.2M EUR-49.5M EUR-7.6M EUR
Basic income (loss) per share (in EUR per share)-0.55 EUR-0.61 EUR-0.09 EUR
Diluted income (loss) per share (in EUR per share)-0.55 EUR-0.61 EUR-0.09 EUR
Basic income (loss) per share from continuing operations (in EUR per share)-0.55 EUR-0.61 EUR-0.09 EUR
Diluted income (loss) per share from continuing operations (in EUR per share)-0.55 EUR-0.61 EUR-0.09 EUR
Basic income (loss) per share from discontinued operations (in EUR per share)0.00 EUR0.00 EUR0.00 EUR
Diluted income (loss) per share from discontinued operations (in EUR per share)0.00 EUR0.00 EUR0.00 EUR

Compare Innate Pharma SA with another company

Corporate structure

Innate Pharma SA sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Innate Pharma SA

  • Novo Filed SCHEDULE 13G/A on Innate Pharma SA, latest Jun 22, 2026 (4 filings since Oct 21, 2025)
  • AstraZeneca Filed SCHEDULE 13D/A on Innate Pharma SA, latest Feb 6, 2026
  • Bpifrance Participations SA Filed SCHEDULE 13D/A on Innate Pharma SA, latest May 7, 2025 (3 filings since Oct 21, 2022)
  • Sanofi Filed SCHEDULE 13G/A on Innate Pharma SA, latest Apr 29, 2025 (2 filings since Apr 29, 2025)
  • Innate Pharma SA I0

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Innate Pharma SA reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents28.1M EUR2 Dec 31, 202566.4M EUR2 Dec 31, 2024−57.7%
Long-term investments10.5M EUR2 Dec 31, 202510.3M EUR2 Dec 31, 2024+1.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)0 EUR2 Dec 31, 20250 EUR2 Dec 31, 2024

Former names

  • Innate Pharma, SAJan 31, 2014 to Jan 31, 20143

Calendar

Coming up

  1. Nov 5, 2026 · Before the openReports results for the quarter ending Sep/202610

Drug trials and FDA: coming up

  1. Jun 2027Phase 2 trial readout expected Phase 2 trial of IPH5201 + durvalumab + standard chemotherapy in Non Small Cell Lung Cancer: primary completion expected Jun 2027 (ClinicalTrials.gov NCT05742607).11

Drug trials and FDA: recently

  1. Jan 8, 2026Phase 2 trial completed Phase 2 trial of IPH4102 in Lymphoma, T-Cell: primary completion Jan 8, 2026, no results posted yet (ClinicalTrials.gov NCT03902184).12

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

237 filings to the SEC since October 2021: 6 annual reports, 10 large holders, 221 other. The latest 20:

  1. Sep 17, 20266-K EDGAR
  2. Sep 17, 20266-K EDGAR
  3. Sep 17, 20266-K EDGAR
  4. Sep 10, 20266-K EDGAR
  5. Sep 2, 20266-K EDGAR
  6. Aug 19, 20266-K EDGAR
  7. Aug 14, 20266-K EDGAR
  8. Aug 10, 20266-K EDGAR
  9. Jul 23, 20266-K EDGAR
  10. Jul 21, 20266-K EDGAR
  11. Jun 22, 2026SCHEDULE 13G/A EDGAR
  12. May 22, 20266-K EDGAR
  13. May 19, 20266-K EDGAR
  14. May 13, 20266-K EDGAR
  15. May 12, 20266-K EDGAR
  16. May 6, 20266-K EDGAR
  17. Apr 23, 20266-K EDGAR
  18. Apr 17, 20266-K EDGAR
  19. Apr 13, 20266-K EDGAR
  20. Apr 13, 20266-K EDGAR

The 237 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Lion Point Capital, LP81,151$149.3K0.7%No change
Morgan Stanley43,524$80.1K0.0%No change
SmartHarvest Portfolios, LLC23,750$43.7K0.0%New
XTX Topco Ltd15,130$27.8K0.0%New
Citadel Advisors LLC12,441$22.9K0.0%New
Jane Street Group, LLC10,310$19.0K0.0%−33,055
Rhumbline Advisers4,719$8.7K0.0%−15
UBS Group AG1,363$2.5K0.0%+502
Farther Finance Advisors, LLC21$380.0%+11
GAMMA Investing LLC9$170.0%−231

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Innate Pharma SA is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARInnate Pharma SA1
  • CIK0001598599
  • LEI9695002Y8420ZB8HJE291
  • Filer statusAccelerated filer not an emerging growth company; not a shell company4
  • Incorporated inFrance4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address117 Avenue De Luminy, Bp 30191, Marseille, France 13009, France1
  • Phone334303030301
  • Shares outstanding93,719,323 shares as of Dec 31, 20254
  • AuditorDeloitte & Associés, Le Bouscat PCAOB ID 1756; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceJan 31, 20141
  • Filings335 in all: 6-K (275), 20-F (7), SCHEDULE 13G/A (5), CORRESP (4), EFFECT (4), UPLOAD (4), 424B5 (3), DRS/A (2)1
    All 30 form types

    DRSLTR (2), F-3 (2), FWP (2), S-8 (2), SC 13D (2), SC 13D/A (2), SC 13G (2), SCHEDULE 13D/A (2), SEC STAFF LETTER (2), 144 (1), 20-F/A (1), 424B4 (1), 8-A12B (1), CERT (1), D (1), DRS (1), F-1 (1), F-1/A (1), F-6 (1), F-6/A (1), POS EX (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (20-F) Apr 1, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing one ordinary share, nominal value €0.05 per shareIPHAThe Nasdaq Global Select Market
Ordinary shares, nominal value €0.05 per shareIPHAThe Nasdaq Global Select Market

From the cover page of the 20-F filed Apr 1, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16